Dapsone-associated methaemoglobinaemia in patients with a haematologic malignancy

Anaesthesia and Intensive Care

Volumn 38, Issue 6, 2010, Pages 1070-1076

  Subramaniam, A ^a   Corallo, C ^a,b   Nagappan, R ^a  

^a BOX HILL HOSPITAL   (Australia)

^b ALFRED HOSPITAL   (Australia)

Author keywords

Anaemia; Dapsone; Fluconazole; Leukaemia; Methaemoglobin; Methaemoglobinaemia; Methylene blue; PJP prophylaxis; Prednisolone; Voriconazole

Indexed keywords

ANTIBIOTIC AGENT; ATENOLOL; ATORVASTATIN; COTRIMOXAZOLE; CYTARABINE; CYTOCHROME P450; DAPSONE; ETOPOSIDE; IDARUBICIN; ISOSORBIDE MONONITRATE; METHEMOGLOBIN; METHYLENE BLUE; OMEPRAZOLE;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ANEMIA; ANTIBIOTIC THERAPY; ARTICLE; BLOOD TRANSFUSION; CLINICAL ARTICLE; DRUG WITHDRAWAL; FEMALE; HEMATOLOGIC MALIGNANCY; HEMOGLOBIN BLOOD LEVEL; HUMAN; INTENSIVE CARE; LEUKEMIA; MALE; METHEMOGLOBINEMIA; OXIMETRY; PANCYTOPENIA; PNEUMOCYSTIS PNEUMONIA; PSEUDOMONAS INFECTION; RETROSPECTIVE STUDY; STEROID THERAPY;

EID: 78650473580     PISSN: 0310057X     EISSN: 14480271     Source Type: Journal    
DOI: 10.1177/0310057x1003800618     Document Type: Article

References (28)

1. Darling R, Roughton F. The effect of methemoglobin on the equilibrium between oxygen and hemoglobin. Am J Physiol 1942; 137:56.
2. Haddad L, Winchester J. Clinical management of poisoning and drug overdose, 3rd ed. Philadelphia, Pennsylvania: Saunders 1998.
3. Olson K. Poisoning and Drug Overdose, 4th ed. New York: McGraw-Hill 2004.
4. Mansouri A, Lurie AA. Concise review: methemoglobinemia. Am J Hematol 1993; 42:7-12.
5. Ash-Bernal R, Wise R, Wright SM. Acquired methemoglobinemia: a retrospective series of 138 cases at 2 teaching hospitals. Medicine (Baltimore) 2004; 83:265-273.
6. Lee GF, Lukens J, Paraskevas F, Greer J, Rodgers G. Wintrobe's Clinical Hematology, Volume 1, 10th ed. Baltimore: Lippincott Williams & Wilkins 1999.
7. Huang L, Morris A, Limper AH, Beck JM. An Official ATS Workshop Summary: Recent advances and future directions in pneumocystis pneumonia (PCP). Proc Am Thorac Soc 2006; 3:655-664.
8. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981; 30:239-245. (Pubitemid 12149145)
9. Clifton Jack 2nd, Leikin JB. Methylene blue. Am J Ther 2003; 10:289-291.
10. Hurford WE, Kratz A. Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 23-2004. A 50-year-old woman with low oxygen saturation. N Engl J Med 2004; 351:380-387.
11. Green H, Paul M, Vidal L, Leibovici L. Prophylaxis of Pneumocystis pneumonia in immunocompromised non-HIV-infected patients: systematic review and meta-analysis of randomized controlled trials. Mayo Clin Proc 2007; 82:1052-1059.
12. Guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients. MMWR Recomm Rep 2000; 49:1-125, CE1-7.
13. Segal BH, Freifeld AG, Baden LR, Brown AE, Casper C, Dubberke E et al. Prevention and treatment of cancer-related infections. J Natl Compr Canc Netw 2008; 6:122-174.
14. Hoyle C, Goldman JM. Life-threatening infections occurring more than 3 months after BMT. 18 UK Bone Marrow Transplant Teams. Bone Marrow Transplant 1994; 14:247-252.
15. Hughes WT, Rivera GK, Schell MJ, Thornton D, Lott L. Successful intermittent chemoprophylaxis for Pneumocystis carinii pneumonitis. N Engl J Med 1987; 316:1627-1632.
16. 2001 USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus. Infect Dis Obstet Gynecol 2002; 10:3-64.
17. Shapiro BA, Peruzzi WT, Templin R, eds. Dyshemoglobinemias, Clinical Application of Blood Gases, 5th ed. St. Louis: Mosby 1994.
18. Lee I, Barton TD, Goral S, Doyle AM, Bloom RD, Chojnowski D et al. Complications related to dapsone use for Pneumocystis jirovecii pneumonia prophylaxis in solid organ transplant recipients. Am J Transplant 2005; 5:2791-2795.
19. Williams S, MacDonald P, Hoyer JD, Barr RD, Athale UH. Methemoglobinemia in children with acute lymphoblastic leukemia (ALL) receiving dapsone for pneumocystis carinii pneumonia (PCP) prophylaxis: a correlation with cytochrome b5 reductase (Cb5R) enzyme levels. Pediatr Blood Cancer 2005; 44:55-62.
20. Budenz AW. Local anesthetics and medically complex patients. J Calif Dent Assoc 2000; 28:611-619.
21. Rosen PJ, Johnson C, McGehee WG, Beutler E. Failure of methylene blue treatment in toxic methemoglobinemia. Association with glucose-6-phosphate dehydrogenase deficiency. Ann Intern Med 1971; 75:83-86.
22. Ohashi K, Yukioka H, Hayashi M, Asada A. Elevated methemoglobin in patients with sepsis. Acta Anaesthesiol Scand 1998; 42:713-716.
23. Coleman MD. Dapsone toxicity: some current perspectives. Gen Pharmacol 1995; 26:1461-1467.
24. Bluhm RE, Adedoyin A, McCarver DG, Branch RA. Development of dapsone toxicity in patients with inflammatory dermatoses: activity of acetylation and hydroxylation of dapsone as risk factors. Clin Pharmacol Ther 1999; 65:598-605.
25. Foxworth JW, Roberts JA, Mahmoud SF. Acquired methemoglobinemia. A case report. Mo Med 1987; 84:187-189.
26. Winter HR, Wang Y, Unadkat JD. CYP2C8/9 mediate dapsone N-hydroxylation at clinical concentrations of dapsone. Drug Metab Dispos 2000; 28:865-868.
27. Grossman S, Budinsky R, Jollow D. Dapsone-induced hemolytic anemia: role of glucose-6-phosphate dehydrogenase in the hemolytic response of rat erythrocytes to N-hydroxydapsone. J Pharmacol Exp Ther 1995; 273:870-877.
28. Flockhart D. Cytochrome P450 Drug Interactions. Indiana 2007.